GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET (2024 - 2030)
The global chemotherapy-based hepatocellular carcinoma (HCC) treatment market was valued at USD 400 million and is projected to reach a market size of USD 601.45 million by the end of 2030. Over the forecast period of 2024–2030, the market is projected to grow at a CAGR of 6%.
HCC, one of the most prevalent primary tumors of the liver, is a solid tumor of the liver. This is a very aggressive tumor that frequently develops in the context of cirrhosis and chronic liver disease. The most significant form of treatment for advanced hepatocellular carcinoma (HCC) is chemotherapy. In the past, this market had limited options and a small presence. Additionally, economic instability persisted, due to which only a very small fraction of the population was able to afford the treatment. Presently, the market has grown significantly owing to extensive efforts in research and developmental activities. In the future, with a growing focus on targeted therapies and personalized medicine, this market is set to see good growth.
Key Market Insights:
By 2027, it is anticipated that spending in the oncology sector will reach over 370 billion dollars. The CAGR for 2023–2027 is projected to be at most 16 percent.
By 2024, it is anticipated that Roche's cancer medicines will bring in 27.8 billion dollars in revenue.
Merck & Co.'s Keytruda produced around 21 billion dollars in sales in 2022, making it the most profitable cancer medicine globally. Patients with hepatocellular carcinoma (HCC) who have had sorafenib therapy in the past are eligible to receive KEYTRUDA.
When it comes to systemic therapy regimens, Lenvatinib and PD-1 inhibitors have been studied in several studies, with conversion success rates ranging from 15.9% to 30.8%. It is also linked to the lowest progressive disease rate and the greatest ORR (36.0–54.2%).
The most prevalent kind of liver cancer, or HCC, is also the fifth most common cause of cancer globally. Therefore, hospitals and other organizations have been taking measures to spread awareness about vaccinations against the hepatitis B virus (HBV). This vaccination is crucial, as a chronic attack of this virus can cause HCC cancer. Additionally, citizens are encouraged to undergo screening programs for early detection and diagnosis
Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market Drivers:
A high number of cancer cases has been creating the need for treatments.
Around 800,000 individuals worldwide receive a diagnosis of this illness every year, according to the American Cancer Society. An estimated 12,000 cases are caused each year in the United States due to this cancer, as per an article by Johns Hopkins University. Various factors contribute to the increasing prevalence of this disease. People who are diagnosed with hepatitis B, hepatitis C, and type 2 diabetes are at greater risk. Additionally, there have been many lifestyle changes over the years. Consumption of alcohol and smoking has increased significantly. Besides, obesity has been on the rise. All these factors have been contributing to ill health and the deaths of millions. Furthermore, many people are not aware of the symptoms of this particular cancer. Only 50% of people can survive for less than two years. Therefore, even though there are limited treatment options that ensure complete success, it is essential to reduce the pain. This demand for the therapies is helping the market grow.
Advancements in R&D activities have been contributing to the success.
Oncology research is one of the most popular and in-demand activities. Many prestigious institutions across the world have been focusing on finding effective remedies to stop tumor growth. To support this, governmental organizations, companies, and other business tycoons have been investing large amounts. The Food and Drug Administration (FDA) has approved various drugs that have proven to reduce the multiplication of tumors. Novel chemotherapeutic drugs, including oxaliplatin, have demonstrated effectiveness in the management of digestive tract malignancies, including colorectal, pancreatic, and stomach tumors. Some of these medications have also been investigated for the treatment of advanced HCC, with encouraging results based on positive outcomes.
The concept of personalized medicine has been facilitating market expansion.
Personalized medicine, also known as precision medicine, is the process where drugs are designed based on the genetic makeup of an individual. Biomarkers are used for this purpose because they provide information about the activities that take place in a cell. There have been many breakthroughs in understanding molecular pathways and other chemical reactions. Over the past ten years, systemic therapy for hepatocellular carcinoma (HCC) has advanced quickly. Physicians may now treat patients with advanced HCC with a greater variety of new medications, including immune checkpoint inhibitors and targeted therapies, either in parallel or sequential fashion.
Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market Restraints and Challenges:
Efficacy, side effects, costs, biomarker validation, and the emergence of other treatment options are the main issues that the market is currently experiencing.
One of the biggest hurdles in the market is the limited efficiency of chemotherapy agents. Few drugs can cause a toxic reaction. They may damage vital organs like the liver, kidneys, heart, lungs, and other reproductive parts. There is always a chance of relapsing with this condition. Secondly, this has been associated with a lot of side effects. Chemotherapies often lead to hair loss, nausea, mouth sores, reduction in immunity, loss of appetite, etc. It takes a toll on the physical and mental health of the individual. Thirdly, cancer treatments are very expensive. They need constant visits to the hospital, which can drain the individual financially. Moreover, the identification of the biomarker is a challenge. HCC is a deadly cancer that has complex molecular profiles. There haven't been many advancements in this regard. Furthermore, surgery, liver transplants, and other radiation therapies have garnered attention. Therefore, people might opt out of the treatment that has the best success rate, causing losses for this market.
Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market Opportunities:
Research and developmental activities are the primary factors that help broaden human knowledge. This field has an ample number of opportunities that benefit this market. Many studies and clinical trials are being carried out to find the most effective drugs. Currently, 115 drugs are in Phase 4. Drug repurposing is being emphasized. This is the process of finding new therapeutic uses for pharmaceuticals that are currently on the market or that are outdated. It is a useful method for finding or creating pharmaceutical compounds with novel pharmacological or therapeutic uses. Furthermore, combination therapies are being prioritized. This involves using chemotherapy along with other treatment options like immunotherapy and other targeted therapies. Apart from this, initiatives are being taken to improve awareness about various kinds of cancer. Governmental bodies have been generating schemes and other strategies to make sure that everybody has equal access to treatment.
GLOBAL CHEMOTHERAPY-BASED HEPATOCELLULAR CARCINOMA TREATMENT MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
6 % |
|
Segments Covered |
By End User and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Bayer AG, Eisai Co., Ltd., Bristol Myers Squibb (BMS), Merck & Co., Inc. (MSD) Roche , AstraZeneca, Jiangsu Hengrui Medicine Co., Ltd., CStone Pharmaceuticals BeiGene, Ono Pharmaceutical Co., Ltd. |
Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market Segmentation:
Market Segmentation: By End-Users:
Based on end-users, in 2023 the hospital segment is the largest segment in the market, holding a share exceeding 50%. The upsurge in this category is mainly because of the advanced treatment options that are offered over here. They offer comprehensive care and facilities that satisfy the needs of the patients, thereby increasing their trust. Secondly, these centers have licensed professionals, which include doctors, nurses, ward boys, and other essential workers. These people have been well equipped with knowledge and can perform various diagnoses, analyze the best possible treatment options, and provide 24/7 care. Apart from this, they offer various services like counseling, which is vital for a few patients to ensure that they have good mental well-being. Specialty clinics are considered to be the fastest-growing end-users in this market. These facilities are focused on a specific cancer type or other disorders. They offer specialized expertise, which includes oncologists and hepatologists who have renowned knowledge regarding different types of liver cancer. Besides, these facilities collaborate with research institutes and other organizations that work on drug discovery and development. This helps in gaining easy access to various chemotherapy drugs. Furthermore, few patients opt for these services, as specialized care is provided to the patients who are admitted. This leads to a more comfortable and trustworthy treatment, ensuring a faster recovery.
Market Segmentation: Regional Analysis:
Based on region, North America is considered to be holding the largest market share in 2023. The region holds a rough share of 34%. Countries like the United States and Canada are at the forefront. This region is known for its advanced healthcare facilities. The hospitals and clinics over here are well equipped with advanced infrastructure facilities, which can include drugs, beds, treatment, doctors, and other necessary services. Secondly, they have a good economy. This means that they have better investments and strength when it comes to carrying out R&D activities. This region has experienced major milestones in drug development and clinical trials. Prestigious institutes like Harvard, Cambridge, Johns Hopkins, Cornell, etc., have been the notable ones. Apart from this, this region has key players like AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and many more who are actively involved in investing, partnerships, and developing oncology medications. Asia-Pacific is the fastest-growing region, with China, Japan, India, and Australia as the leading countries. This region holds an approximate share of 23%. One major factor in this is the rising incidence of HCC cancer cases. This is attributed to changes in lifestyle and diet. Secondly, significant progress has been made in spreading awareness. Various training activities and campaigns have been hosted by academic institutes and other major companies. This has led to the early detection of the disease. Thirdly, improving economic conditions have been responsible for the elevation. The funds allocated are being increased. This is leading to technological upgrades and extensive R&D activities. Furthermore, pharmaceutical companies have global operations, leading to increased partnerships and drug other advancements.
COVID-19 Impact Analysis on the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market:
The pandemic hurt the market. Lockdowns, social isolation, and movement restrictions were the new norm. This caused a lot of disruptions in the supply chain, transportation, and other logistics. Routine screenings and the diagnosis of cancer were delayed. People were afraid to step out owing to virus contamination. Besides, cancer and other immunity-suppressed patients had a higher risk of coronavirus, due to which postponement and cancellation of appointments were observed. There was a lot of uncertainty due to financial restraints. Layoffs became common, and people were losing their jobs. Many of them were unable to afford treatments and other necessary facilities. An economic downfall was observed due to this. There was a shift in priorities, which included investments and clinical trials. Researchers were giving prominence to the vaccine development of the coronavirus. Furthermore, there was a decrease in cancer cases. The National Institute of Health stated that an online survey conducted in the Asian region reported a 26.7% decrease in the number of HCC cancer cases during the pandemic. Post-pandemic, the market has picked up with the resumption of R&D activities and technological adoption.
Latest Trends/ Developments:
The companies in this market are motivated to achieve a higher market share by implementing different strategies, such as acquisitions, partnerships, and investments. This has further resulted in increased enlargement.
To treat HCC, there has been a shift towards combining immunotherapy drugs, such as immune checkpoint inhibitors like pembrolizumab and nivolumab, with chemotherapy. Research and experimental trials are assessing the effectiveness of integrating immunotherapies with chemotherapy to improve patients' responsiveness to treatment and overall survival.
Key Players:
In December 2022, Replimune and Roche signed a clinical collaboration agreement for the development of RP3 in hepatocellular carcinoma and colorectal cancer. For the first- and second-line therapy of hepatocellular carcinoma (HCC) as well as the third-line treatment of colorectal cancer (CRC), RP3 will be developed in conjunction with Bevacizumab and Atezolizumab.
In August 2022, BeiGene, a biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, announced that the global Phase 3 rationale 301 trial with tislelizumab as a first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC) met its primary endpoint of non-inferior overall survival (OS) versus sorafenib. Tislelizumab's safety profile matched that of earlier research, and no new safety signals were noted.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The global chemotherapy-based hepatocellular carcinoma (HCC) treatment market was valued at USD 400 million and is projected to reach a market size of USD 601.45 million by the end of 2030. Over the forecast period of 2024–2030, the market is projected to grow at a CAGR of 6%.
A high number of cancer cases, advancements in R&D activities, and personalized medicine are the main factors propelling the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market.
Based on End-Users, the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market is segmented into Hospitals, Specialty Clinics, Research Institutes, and Others.
North America is the most dominant region for the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market.
Bayer AG, Eisai Co., Ltd., and Bristol Myers Squibb (BMS) are the key players operating in the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
